

*[Press Release – For Immediate Release]*



*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 575)**

## **Update on NDA status for Fortacin™/Senstend™ in China**

### **Positive Progress at Deep Longevity**

(22 July 2025, Hong Kong) – Regent Pacific Group Limited (“**Regent Pacific**” or the “**Company**” and collectively with its subsidiaries, the “**Group**”; stock code: 0575.HK) is pleased to announce that its commercial strategic partner Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. (“**Wanbang Biopharmaceutical**”, a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd.) is progressing the new drug application (“**NDA**”) for Senstend™ with the National Medical Products Administration (“**NMPA**”) in China. In this respect, Wanbang Biopharmaceutical has received the first round of questions from NMPA on the NDA dossier and it has submitted in return a timely and fulsome response.

In support of the NDA application, Wanbang Biopharmaceutical has submitted 900 commercial samples of Senstend™ that were manufactured by its manufacturing partner to the Centre of Drug Evaluation.

Wanbang Biopharmaceutical remains optimistic that NDA approval will be obtained by the end of 2025, with first commercial launch starting in Q1 2026.

**Jamie Gibson, CEO of the Group**, said, “We are delighted with the progress that Wanbang Biopharmaceutical is undertaking with the NDA and we look forward to the continued progress of the NDA dossier with NMPA, with approval expected by the end of 2025.”

If the NMPA grants an import licence for Senstend™, US\$5 million (or approximately HK\$39 million) (before deduction of PRC withholding tax) will be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend™ in China, US\$2 million (or approximately HK\$15.60 million) (before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical. Also, and as disclosed in the Company’s

announcement on 25 March 2025, there are other significant payments payable to the Group from Wanbang Biopharmaceutical in respect of commercial milestones and royalties.

### **Positive Progress at Deep Longevity**

Deep Longevity, Inc, a wholly-owned subsidiary of the Company, ("Deep Longevity") is making continued progress with the onboarding of new customers during the first half of this year, with notable new customers being Humansa Health (<https://www.humansahealth.com>), Hong Kong and Holistica World (<https://www.holisticaworld.com>), India. Furthermore, usage of the company's aging clocks by customers has increased in the first half of the year as compared to the same period last year, indicating the value of the technology and the increased focus of longevity and wellness as a health trend. Deep Longevity aims to create new partnerships with longevity apps, other platforms, startups and diagnostic companies that have a B2C model.

Deep Longevity is committed to launching aging clocks in the United States ("US"), being the largest market for longevity, with the recruitment of a US president to lead the expansion into this market, which is expected to drive the growth of the business. It should be stressed that while the longevity and wellness market is in its infancy, this unique technology is designed to provide entry into this extremely large and growing market worth over US\$6.3 trillion in 2023.

Deep Longevity has an active pipeline, with the larger discussions ongoing with multiple longevity clinics and other companies interested in using our aging clocks in markets such as Brazil, Germany, and Southeast Asia.

Deep Longevity has also updated its aging clock with Biometric Age that uses 17 blood biomarkers and 4 biometric measures, including blood pressure and waist circumference, providing additional measurements to customers. In addition, Deep Longevity is constantly updating its large language model, which provides more accurate BloodAge and MindAge reports.

Deep Longevity is undertaking further R&D to add a new clock to its product range, called 'Face Age' or a 'Face Index Score.' In addition, Deep Longevity is exploring the addition of other new clocks to its existing product range, focused on the health, beauty, and wellness sectors.

*-Ends-*

### **About Senstend™**

Senstend™ (the brand name for Fortacin™ in China) is a metered dose aerosol from a proprietary formulation of two marketed drugs, lidocaine and prilocaine, developed for treating premature ejaculation (“PE”). The disorder affects approximately 20% to 30% of men in China, which translates to a significant initial target male PE population base of approximately 55 million men in China aged between 20-59 years old, based on World Bank population estimates of 2022 rising to over 170 million men. In December 2018, Plethora Solutions Limited, a wholly-owned subsidiary of the Company, signed an exclusive license agreement with Wanbang Biopharmaceutical, to market, distribute and sell Senstend™ for PE in China.

### **About Deep Longevity**

Deep Longevity is a wholly owned subsidiary of Regent Pacific Group Limited, developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, which enables physicians to make better decisions on the interventions that may slow down or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age.

### **About Regent Pacific Group Limited (Stock code: 0575.HK)**

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US\$298 million to shareholders since its initial public offering in May 1997.

[www.regentpac.com](http://www.regentpac.com)

This press release is distributed by LBS Communications Consulting Limited.

### **For media inquiries, please contact:**

Joanne Chan      Tel: (852)3679 3671      Email: [jchan@lbs-comm.com](mailto:jchan@lbs-comm.com)

The English version of this press release shall prevail in case of any discrepancy or inconsistency between the English version and its Chinese translation.